Bain, S., Verma, S., McGuire, D. K., Bhatt, D. L., Leiter, L. A., Mazer, C. D., . . . Buse, J. B. (2020). Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes, Obesity and Metabolism, 22(12), pp. 2487-2492. doi:10.1111/dom.14160

Bain, Steve, et al. "Effects of Glucagon-like Peptide-1 Receptor Agonists Liraglutide and Semaglutide On Cardiovascular and Renal Outcomes Across Body Mass Index Categories in Type 2 Diabetes: Results of the LEADER and SUSTAIN 6 Trials." Diabetes, Obesity and Metabolism 22, no. 12 (2020): 2487-2492.

Bain, Steve, et al. "Effects of Glucagon-like Peptide-1 Receptor Agonists Liraglutide and Semaglutide On Cardiovascular and Renal Outcomes Across Body Mass Index Categories in Type 2 Diabetes: Results of the LEADER and SUSTAIN 6 Trials." Diabetes, Obesity and Metabolism 22.12 (2020): 2487-2492.